Skip to content
1887

Abstract

The Ebola virus (EBV) genus is responsible for severe viral haemorrhagic illness caused by a group of viruses belonging to the Filoviridae family. Five species have been identified as causative agents for Ebola virus disease (EVD). The EBV (Zaire) strain is the most predominant organism involved in recorded EVD outbreaks and has been reported as the most virulent. EVD was first identified in the Democratic Republic of Congo in 1976 and has occurred in sporadic outbreaks over the last few decades with the most recent episode in Uganda over the period September 2022–January 2023. EVD is zoonotic in nature with bats as reservoir host and humans become infected via a spillover event from contact with infected animals. EVD is transmitted through contact with infected bodily fluids. It is considered fatal with a high mortality and high infectivity rate. Treatment is generally supportive with the availability of intravenous fluids and medicines. Research into vaccine development is ongoing. EVD is a particular public health concern given the potential for global spread during an outbreak.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001998
2025-07-03
2025-07-10
Loading full text...

Full text loading...

/deliver/fulltext/jmm/74/7/jmm001998.html?itemId=/content/journal/jmm/10.1099/jmm.0.001998&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO) Ebola virus disease, Fact sheet N°103, September 2014; 2014 https://web.archive.org/web/20141214011751/https://www.who.int/mediacentre/factsheets/fs103/en/
  2. Awah PK, Boock AU, Kum KA. Ebola virus diseases in Africa: a commentary on its history, local and global context. Pan Afr Med J 2015; 22 Suppl 1:18 [View Article] [PubMed]
    [Google Scholar]
  3. Li YH, Chen SP. Evolutionary history of Ebola virus. Epidemiol Infect 2014; 142:1138–1145 16 Sep 2013 [View Article] [PubMed]
    [Google Scholar]
  4. Centers for Disease Control and Prevention (CDC) Outbreak History | Ebola; 2024 https://www.cdc.gov/ebola/outbreaks/index.html accessed 24 February 2024
  5. Weisberg AJ, Elmarakeby HA, Heath LS, Vinatzer BA. Similarity-based codes sequentially assigned to ebolavirus genomes are informative of species membership, associated outbreaks, and transmission chains. Open Forum Infect Dis 2015; 2:ofv024 [View Article] [PubMed]
    [Google Scholar]
  6. West TE, von Saint André-von Arnim A. Clinical presentation and management of severe Ebola virus disease. Ann Am Thorac Soc 2014; 11:1341–1350 [View Article] [PubMed]
    [Google Scholar]
  7. Izudi J, Bajunirwe F. Case fatality rate for Ebola disease, 1976-2022: a meta-analysis of global data. J Infect Public Health 2024; 17:25–34 [View Article] [PubMed]
    [Google Scholar]
  8. Jacob ST, Crozier I, Fischer WA 2nd, Hewlett A, Kraft CS et al. Ebola virus disease. Nat Rev Dis Primers 2020; 6:13 [View Article] [PubMed]
    [Google Scholar]
  9. Goldstein T, Anthony SJ, Gbakima A, Bird BH, Bangura J et al. Author correction: the discovery of bombali virus adds further support for bats as hosts of ebolaviruses. Nat Microbiol 2018; 3:1486 [View Article] [PubMed]
    [Google Scholar]
  10. Feldmann H, Sprecher A, Geisbert TW, Ebola N. Engl J Med 2020; 382:1832–1842 [View Article]
    [Google Scholar]
  11. Beitzel BF, Radoshitzky SR, Di Paola N, Brannan JM, Kimmel D et al. On-demand patient-specific phenotype-to-genotype Ebola virus characterization. Viruses 2021; 13:2010 [View Article] [PubMed]
    [Google Scholar]
  12. Bettini A, Lapa D, Garbuglia AR. Diagnostics of Ebola virus. Front Public Health 2023; 11:1123024 [View Article] [PubMed]
    [Google Scholar]
  13. Willet V, Dixit D, Fisher D, Bausch DG, Ogunsola F et al. On behalf of the guideline development group, summary of WHO infection prevention and control guideline for ebola and marburg disease. BMJ 2024; 384:2811 [View Article]
    [Google Scholar]
  14. Government of Canada Ebola disease: for health professionals and humanitarian aid workers, Government of Canada Health webpage; 2025Jan27 https://www.canada.ca/en/public-health/services/diseases/ebola/health-professionals-ebola.html
  15. Ramharter M, Günther S. Evaluating case definitions for Ebola virus disease. Lancet Infect Dis 2020; 20:1224–1226 [View Article] [PubMed]
    [Google Scholar]
  16. Martin P, Laupland KB, Frost EH, Valiquette L. Laboratory diagnosis of Ebola virus disease. Intensive Care Med 2015; 41:895–898 [View Article] [PubMed]
    [Google Scholar]
  17. Uyeki TM, Mehta AK, Davey RT, Liddell AM, Wolf T et al. For the working group of the U.S european clinical network, clinical management of ebola virus disease patients in the U.S. N Engl J Med 2016; 374:636–646 [View Article]
    [Google Scholar]
  18. Katz LM, Tobian AAR. Ebola and transfusion medicine. Transfusion 2014; 54:3247–3251 [View Article]
    [Google Scholar]
  19. Iwen PC, Smith PW, Hewlett AL, Kratochvil CJ, Lisco SJ et al. Safety considerations in the laboratory testing of specimens suspected or known to contain Ebola virus. Am J Clin Pathol 2015; 143:4–5 [View Article] [PubMed]
    [Google Scholar]
  20. World Health Organization (WHO) Therapeutics for Ebola Virus Disease Geneva: World Health Organization; 2022
    [Google Scholar]
  21. El Ayoubi LW, Mahmoud O, Zakhour J, Kanj SS. Recent advances in the treatment of Ebola disease: a brief overview. PLoS Pathog 2024; 20:e1012038 [View Article] [PubMed]
    [Google Scholar]
  22. Fausther-Bovendo H, Kobinger G. The road to effective and accessible antibody therapies against Ebola virus. Curr Opin Virol 2022; 54:101210 [View Article] [PubMed]
    [Google Scholar]
  23. Barbiero VK. Ebola: a hyperinflated emergency. Glob Health Sci Pract 2020; 8:178–182 [View Article] [PubMed]
    [Google Scholar]
  24. Kadanali A, Karagoz G. An overview of Ebola virus disease. North Clin Istanb 2015; 2:81–86 [View Article] [PubMed]
    [Google Scholar]
  25. Rivera A, Messaoudi I. Molecular mechanisms of Ebola pathogenesis. J Leukoc Biol 2016; 100:889–904 [View Article] [PubMed]
    [Google Scholar]
  26. Yamaoka S, Ebihara H. Pathogenicity and virulence of Ebolaviruses with species- and variant-specificity. Virulence 2021; 12:885–901 [View Article] [PubMed]
    [Google Scholar]
  27. Caleo G, Theocharaki F, Lokuge K, Weiss HA, Inamdar L et al. Clinical and epidemiological performance of WHO Ebola case definitions: a systematic review and meta-analysis. Lancet Infect Dis 2020; 20:1324–1338 [View Article] [PubMed]
    [Google Scholar]
  28. Jain S, Khaiboullina S, Martynova E, Morzunov S, Baranwal M. Epidemiology of Ebolaviruses from an etiological Perspective. Pathogens 2023; 12:248 [View Article] [PubMed]
    [Google Scholar]
  29. Ohimain EI, Silas-Olu D. The 2013-2016 Ebola virus disease outbreak in West Africa. Curr Opin Pharmacol 2021; 60:360–365 [View Article] [PubMed]
    [Google Scholar]
  30. Malik S, Kishore S, Nag S, Dhasmana A, Preetam S et al. Ebola virus disease vaccines: development, current perspectives & challenges. Vaccines 2023; 11:268 [View Article] [PubMed]
    [Google Scholar]
  31. Sharma AR, Lee Y-H, Nath S, Lee S-S. Recent developments and strategies of Ebola virus vaccines. Curr Opin Pharmacol 2021; 60:46–53 [View Article] [PubMed]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001998
Loading
/content/journal/jmm/10.1099/jmm.0.001998
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error